Variantyx

Company profile

About Variantyx

Variantyx is a molecular diagnostics company that is setting the standard in genome analysis by offering the most comprehensive diagnostic testing clinically available for genetic conditions. The company disrupts traditional testing approaches with its advanced proprietary technology, including PCR-free whole genome sequencing (WGS) paired with Genomic Intelligence® analytical software. Variantyx's methodology enables thorough interrogation of the genome with the ability to detect all major clinically relevant variant types from a single sample, generating uniform coverage of over 98% of a patient's DNA compared to PCR-based panel and exome technologies that cover only 1-2%. The company's flagship product, Genomic Unity® 2.0, sequences each patient's genome twice using both short-read and long-read sequencing for ultimate diagnostic capability. Variantyx offers a wide variety of test options ranging from targeted analyses focusing on pre-curated panels of indication-relevant genes to comprehensive analyses that consider all genes. All tests are performed on a whole genome platform, making it easy to start with a targeted analysis and automatically reflex up to a comprehensive analysis if the first test is non-diagnostic, without requiring additional samples or sequencing. The company serves healthcare providers, health systems, and patients across rare genetic disorders, neurology, rapid genome analysis for NICU, reproductive genetics, hereditary cancer, and wellness testing. Variantyx's mission is to improve the quality of life of patients with state-of-the-art genomic tests and personalized medicine based on advanced laboratory technology, proprietary AI/ML analytical tools, and a world-class clinical team.

Company description · Variantyx official website